Inflammatory prognostic markers in clear cell renal cell carcinoma - Preoperative C -reactive protein does not improve predictive accuracy

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  Bedke, Jens ^a   Chun, Felix K H ^b   Merseburger, Axel ^c   Scharpf, Marcus ^a   Kasprzyk, Kathrin ^a   Schilling, David ^a   Sievert, Karl Dietrich ^a   Stenzl, Arnulf ^a   Kruck, Stephan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Biomarkers; CRP; Predictive accuracy; Renal cell cancer; Systemic inflammation; Threshold; WBC

Indexed keywords

C REACTIVE PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; INFLAMMATION; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR VOLUME; BLOOD; COMPARATIVE STUDY; GERMANY; KIDNEY TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; REPRODUCIBILITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; FEMALE; GERMANY; HUMANS; INFLAMMATION; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

MLCS; MLOWN;

EID: 84876445102     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11642.x     Document Type: Article

References (39)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36
2. Kruck S, Bedke J, Kuczyk MA, Merseburger AS. Second line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 2012; 12: 777-85
3. Karakiewicz PI, Suardi N, Capitanio U et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 2009; 55: 287-95
4. Bedke J, Buse S, Pritsch M et al. Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences. BJU Int 2009; 103: 1349-54
5. Ljungberg B, Cowan NC, Hanbury DC et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58: 398-406
6. Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol 2009; 181: 1020-7
7. Maxine S, Shahrokh FS, Christopher C et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 2011; 60: 644-61
8. Kruck S, Merseburger AS, Hennenlotter J et al. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int 2012; 109: 1565-70
9. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45
10. Kataoka H, Tanaka H, Nagaike K, Uchiyama S, Itoh H. Role of cancer cell-stroma interaction in invasive growth of cancer cells. Hum Cell 2003; 16: 1-14
11. Bedke J, Stenzl A. Immunologic mechanisms in RCC and allogeneic renal transplant rejection. Nat Rev Urol 2010; 7: 339-47
12. Bedke J, Laske K, Feyerabend S et al. 76 Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma. Eur Urol 2012; 11: e76 - ea
13. Whiteside T. The role of immune cells in the tumor microenvironment the link between inflammation and cancer. In Dalgleish AG, Haefner B eds, The Link Between Inflammation and Cancer: Wounds That Do Not Heal, Vol. 130. New York: Springer, 2006: 103-24
14. Wu Y, Fu X, Zhu X et al. Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2011; 137: 887-96
15. Gakis G, Todenhofer T, Renninger M et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int 2011; 108: 1800 - 5
16. Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 2009; 32: 471-82
17. Johnson TV, Abbasi A, Owen-Smith A et al. Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology 2010; 76: 766 e1-5
18. Iimura Y, Saito K, Fujii Y et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 2009; 181: 1004-12
19. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007; 109: 205-12
20. Negrier S, Gomez F, Douillard JY et al. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. World J Urol 2005; 23: 161-5
21. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-63
22. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982; 247: 2543-6
23. Taylor JM, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Res 2008; 14: 5977-83
24. Tillett WS, Francis T. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med 1930; 52: 561-71
25. Saito K, Kihara K. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 2011; 8: 659-66
26. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7
27. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009; 27: 4709-17
28. Karakiewicz PI, Hutterer GC, Trinh QD et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 2007; 110: 1241-7
29. Jagdev SP, Gregory W, Vasudev NS et al. Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 2010; 103: 1649-56
30. Takayama T, Sugiyama T, Kai F et al. Characteristics of aggressive variants in T1a renal cell carcinoma. J Cancer Res Clin Oncol 2011; 137: 1653-9
31. Saito K, Tatokoro M, Fujii Y et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 2009; 55: 1145-53
32. Manola J, Royston P, Elson P et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group. Clin Cancer Res 2011; 17: 5443-50
33. Panichi V, Migliori M, De Pietro S et al. C reactive protein in patients with chronic renal diseases. Ren Fail 2001; 23: 551-62
34. Shlipak MG, Fried LF, Crump C et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 87-92
35. Ramsey S, Lamb GW, Aitchison M, McMillan DC. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int 2008; 101: 959-63
36. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6-11
37. Menon V, Greene T, Wang X et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766-72
38. Karakiewicz PI, Briganti A, Chun FK et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25: 1316-22
39. Walter S, Weinschenk T, Stenzl A et al. Prolonged survival of patients with advanced renal cancer responding to multi-peptide vaccine IMA901 after single-dose cyclophosphamide. Nat Med 2012; 18: 1254-61